

Duarte, CA 91010-3000 Phone G26-920-5445 Fax 626-301-9115 imagruson a cohors www.c.typ/hope.org

December 11, 2017

Municipal Securities Rulemaking Board Electronic Municipal Market Access (EMMA) 1900 Duke Street, Suite 600 Alexandria, VA 22314

DAC Bond 315 East Robinson Street, Suite 300 Orlando, Florida 32801

RE: City of Hope continuing disclosure for the twelve months ended September 30, 2017 for: (1) the Series 2012 A Revenue Bonds through the California Health Facilities Financing Authority issued on November 15, 2012 CUSIP #s 13033LK71, 13033LK89, 13033LK97, 13033LL21, 13033LL39, 13033LL47, 13033LL54, 13033LL62, 13033LL70, 13033LL88, 13033LL96, 13033LM20, 13033LM38, 13033LM46, 13033LM95, 13033LM53, 13033LM79, 13033LM87, 13033LM61, 13033LN29, 13033LN37; (2) City of Hope Direct Obligation Notes, Series 2013 (Taxable) issued on July 25, 2013 (the "Series 2013 Notes") CUSIP # 17858PAA9; and (3) Series 2017 B Variable Rate Revenue Bonds and Series 2017 C Variable Rate Revenue Bonds through the California Health Facilities Financing Authority issued on February 10, 2017.

To Whom It May Concern:

Enclosed in this package are the following items:

Unaudited combining financial statements for the year September 30, 2017;

The enclosed disclosure information is informational and comes ahead of the year end audited financial statement disclosures and the Management Discussion and Analysis, which are due 150 days after the fiscal year end.

Any questions or comments on the above information should be addressed to the undersigned by email at cvandenberg@coh.org.

Sincerely,

Cornelis van den Berg Interim Chief Financial Officer

CvdB/vtm

cc: Rating Agencies

Mr. Randall Beatty, Chair, City of Hope Board of Directors Audit Committee Mr. Ronald Sargeant, Chair, City of Hope Board of Directors Finance Committee

CITY OF HOPE AND AFFILIATES

Consolidated Financial Statements

For the Year Ended September 30, 2017 and 2016

UNAUDITED

Consolidated Statements of Financial Position (In Millions)

	Sej	otember 2017	September 2016		
Assets				-	
Current assets:					
Cash and cash equivalents	\$	212.1	\$	121.5	
Investments		1,192.0		1,083.2	
Self-insurance trust funds		3.3		3.6	
Patient accounts receivable		245.1		243.5	
Grants and other receivables		66.1		66.3	
Due from third party payors		9.8		3.9	
Donor-restricted unconditional promises to give, net		49.4		22.3	
Prepaid and other		36.7		28.9	
Total current assets		1,814.5		1,573.2	
Property and equipment, net		861.9		722.7	
Other assets:					
Investments		313.8		357.6	
Board-designated assets		815.6		715.2	
Donor-restricted assets:					
Investments		442.9		345.9	
Unconditional promises to give, net		54.0		86.8	
Contributions receivable from annuity and split-inte	rest				
agreements, net		13.6		15.1	
Other		3.6		1.6	
Intangible assets		6.1		2.8	
Other technology		4.6			
Other long-term assets		53.2		44.9	
Total other assets		1,707.4		1,569.9	
Total assets	\$	4.383.8	\$	3.865.8	

Consolidated Statements of Financial Position (In Millions)

		otember 2017	September 2016		
Liabilities and net assets	77030466				
Current liabilities:					
Accounts payable and accrued liabilities	\$	157.1	\$	139.8	
Accrued salaries, wages and employee benefits		68.8		58.3	
Long-term debt, current portion		11.6		90.6	
Deferred revenue		27.3		23.1	
Other		0.8		0.4	
Total current liabilities		265.6		312.2	
Long-term debt, net of current portion		683.4		618.3	
Annuity and split-interest agreement obligations		18.6		17.3	
Deferred rent		14.0		10.6	
Interest rate swap		10.3		16.9	
Other	64	56.5		38.2	
Total liabilities		1,048.4		1,013.5	
Net assets:					
Unrestricted		2,788.5		2,395.4	
Temporarily restricted		370.8		288.5	
Permanently restricted	-	176.1		168.4	
Total net assets		3,335.4		2,852.3	
Total liabilities and net assets	\$	4,383.8	\$	3,865.8	

Consolidated Statements of Activities (In Millions)

Year Ended September 30, 2017

	Hni	restricted		porarily stricted	Permanently Restricted	Total
Revenues:	Oill	CSTITUTE	146	Stricted	Restricted	TOTAL
Contributions (including net special events)	\$	64.1	S	72.8	S 7.4	\$ 144.3
Net patient service revenues		1.186.2				1,186.2
Research grants		135.1			•	135.1
Investment income		138.8		13.4	0.2	152.4
Net unrealized gain on investments		154.2		15.1		169.3
Royalty and licensing income		398.1				398.1
Other		23.5		0.2	=	23.7
Total revenues	-	2.100.0		101.5	7.6	2.209.1
Net assets released from restrictions		44.6		(44.6)	•	-
Total revenues and other increases		2.144.6		56.9	7.6	2,209.1
Expenses:						
Salaries, wages and benefits		613.7		~		613.7
Purchased services		274.0		-		274.0
Professional fees		145.3		•		145.3
Pharmaceuticals and supplies		376.6				376.6
Equipment rental and maintenance		22.6		-	•	22.6
Interest		27.3		• 1	-	27.3
Change in FV of interest rate swap		(6.7)		-	-	(6.7)
Depreciation and amortization		119.2		-	(4)	119.2
Occupancy		24.6		•	•	24.6
Royalty sharing expense		123.0			-	123.0
Hospital provider fee		7.6		-	-	7.6
Bad debt		7.4		•		7.4
Goodwill impairment		3.9		•		3.9
Other		33.9			•	33.9
Total expenses		1.772.4		-	-	 1,772.4
Changes in net assets		372.2		56.9	7.6	436.7
Unrestricted and restricted contribution from affiliati	on	20.9		25.4	0.1	46.4
Total changes in net assets		393.1		82.3	7.7	483.1
Net assets, beginning of year		2,395.4		288.5	168.4	2,852.3
Net assets, end of year	S	2,788.5	\$	370,8	\$ 176.1	\$ 3,335,4

Consolidated Statements of Activities (In Millions)

Year Ended September 30, 2016

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
Revenues:	Curestitetea	14050116164	1000111000	
Contributions (including net special events)	\$ 53.7	\$ 71.6	\$ 6.0 \$	131.3
Net patient service revenues	1,119.8			1,119.8
Research grants	87.8	1,50	<u></u>	87.8
Investment income	80.6	7.8	(0.4)	88.0
Net unrealized gain on investments	99.6	10.0	•	109.6
Royalty income	333.7			333.7
Other	22.2	0.2	2	22.4
Total revenues	1,797.4	89.6	5.6	1,892.6
Net assets released from restrictions	32.5	(32.5)		-
Total revenues and other increases	1.829.9	57.1	5.6	1,892.6
Expenses:				
Salaries, wages and benefits	522.8	-	-	522.8
Purchased services	187.0		-	187.0
Professional fees	131.3	-	-	131.3
Pharmaceuticals and supplies	338.9	-	_	338.9
Equipment rental and maintenance	19,4	-		19.4
Interest	32.4	-	**	32.4
Change in FV of interest rate swap	5.9	-	•	5.9
Depreciation and amortization	95.1	-	t=.	95.1
Occupancy	18.4			18.4
Royalty sharing expense	102.1	- 51	4	102.1
Hospital provider fee	13.9	÷.	-	13.9
Bad debt	3.1	•		3.1
Other	19.2	-	(<u>*</u>	19.2
Total expenses	1,489.5	-		1,489.5
Changes in net assets	340.4	57.1	5.6	403.1
Change in donor designation of net assets	S#0.	7.0	(7.0)	:•
Net assets, beginning of year	2.055.0	224.4	169.8	2,449.2
Net assets, end of year	\$ 2,395.4	\$ 288.5	\$ 168.4 \$	2,852.3

Consolidated Statements of Cash Flows (In Millions)

		September 2017		September 2016	
Operating activities					
Changes in net assets	\$	483.1	\$	403.1	
Adjustments to reconcile changes in net assets to net cash provided by					
operating activities:					
Depreciation and amortization		118.9		95.1	
Amortization of bond issue costs		0.3		0.3	
Contribution from affiliation		(46.4)		•	
Loss on sale of contributed real property		-		1.0	
Loss on disposal of fixed assets		1.2		2.2	
Gain on equity based investment holdings		(49.6)		(26.4)	
Loss on impairment of intangible assets		3.9		-	
Provision for bad debt		7.8		3.1	
Net unrealized gain on investments		(180.4)		(109.7)	
(Gain) loss from change in value of interest rate swap agreement		(6.7)		5.9	
Contribution proceeds restricted for endowment		(5.3)		(4.8)	
Changes in assets and liabilities:					
Patient accounts receivable, net		(8.6)		(40.5)	
Grants and other receivables		5.8		(17.2)	
Unconditional promises to give, net		15.1		(20.4)	
Contributions receivable from split-interest agreements		1.5		(7.1)	
Contributed real property held for sale		0.5		(2.2)	
Other assets		(20.4)		(6.1)	
Accounts payable and accrued liabilities		(25.9)		18.5	
Accrued salaries, wages, and employee benefits		9.0		4.6	
Annuity and split-interest agreement obligations		1.3		0.4	
Other liabilities		(1.9)		(2.5)	
Net cash provided by operating activities before net purchases of trading investments		303.2		296,4	
Net sales (purchases) of trading investments		33.6		(97.6)	
Net cash provided by operating activities		336.8		198.8	
		550.0		170,0	
Investing activities Increase in notes receivable		(2.0)		(2.7)	
		(3.0)		(2.7)	
Additions to property and equipment		(200.2)		(85.8)	
Proceeds from sale of contributed real property held for sale		0.1		1.0	
Cash from Affiliation		10.6		(110.7)	
Net purchases of alternative investments		(50.9)		(119.7)	
Net cash used in investing activities		(243.4)	Ų.	(207.2)	
Financing activities					
Repayment of long-term debt		(65.0)	1	≅ 7	
Proceeds from long-term debt borrowing		67.9			
Principal payments on long-term debt		(11.0))	(8.2)	
Contribution proceeds restricted for endowment		5.3		4.8	
Net cash used in financing activities		(2.8)		(3.4)	
Net increase (decrease) in cash and cash equivalents		90.6		(11.8)	
Cash and cash equivalents, beginning of year		121.5		133.3	
Cash and cash equivalents, end of year	\$	212.1	\$	121.5	